I recall someone did remark about a conversation in which the person (ENMD) was asked the question concerning data mining...
However,I seem to recall when 2ME2 was suggested as a treatment for RA it was based upon responses from some of the patients enrolled in the trials... hazy as my memory might be, I have to believe there was at least some reason to pursue the potential based upon observable response...
Mobery, you are the guy jousting with windmills...you seem to demand absolute answers on Entremed... if this were possible,we would all be living in Bill Gates neighborhood...
Is there anyone on this board who doesn't understand the volatility of this stock and the risk involved???
Yes, there have been set-backs... but is the only choice failure??? As long as there are drug candidates and funds to continue with the trials... there are still possibilities for success or failure... Although, I do understand the risk side, I didn't invest in failure...so why dwell on that side at this point... the lights are still on...
Importantly, 2ME2 (Panzem) was inherited by Burns... it has been around for long time... he did what he could with it... recognizing that the clinical results showed no clear path towards approval was an important decision...
Market Data 
Markets 
AI
